References
- Trishler P V, Woodward B, O'Connor J, et al. High prevalence of AIP in a psychiatric patient population. Am J Psychiatry 1985; 142: 1430–6
- Stein J A, Tschudy D P. Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine 1970; 49: 1–16
- King P H, Bragdon A C. MR1 reveals multiple reversible cerebral lesions in an attack of AIP. Neurology 1991; 41: 1300–02
- Tephly T R, Hasegawa E, Baron J. Effect of drugs on haem syndiesis in the liver. Metabolism 1971; 20: 200–214
- Smith A G, De Matteis F. Drugs and the hepatic porphyrias. Clinics in haematology-the porphyrias, A Goldberg, M R Moore. WB Saunders, Philadelphia. 1980; 339–425
- Cooper S A, Collacott R A. Clinical features and diagnostic criteria of depression in Down's syndrome. Br J Psychiatry 1994; 165: 399–403
- Cooper S A, Collacott R A. Depressive episodes in adults with learning disabilities. Irish J Psychol Med 1996; 13: 105–113
- Dover S B, Graham A, Moore M R, McColl K EL. Lofepramine-a safe antidepressant in acute intermittent porphyria. J Psychopharmacol 1994; 8: 104–108
- Krummel S J, Wesner R B. Exacerbation of AIP by nortriptyline. Drug Intell Clin Pharm 1986; 20: 487–8
- Moore M R, McColl K EL. The effects of some chemotherapeutic and immunosuppressive agents on 5-amino-laevulinate synthase. Trans Biochem Soc 1987; 15: 679–80
- Vaz F J, Salcedo M S. Fluoxetine treatment of depressive symptoms in AIP (letter). J Clin Psychiatry 1991; 52: 3